These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 9553407

  • 1. [The significance of converting enzyme inhibitor angiotensin I to angiotensin II in treatment of patients with coronary disease].
    Halawa B.
    Pol Merkur Lekarski; 1998 Jan; 4(19):32-4. PubMed ID: 9553407
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. [Angiotensin converting enzyme inhibitors in ischemic heart disease].
    Takác M, Koval S, Takác V, Takác P.
    Vnitr Lek; 1996 Apr; 42(4):290-6. PubMed ID: 8693718
    [Abstract] [Full Text] [Related]

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 5. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.
    Lévy S.
    Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):220-5. PubMed ID: 16568131
    [Abstract] [Full Text] [Related]

  • 6. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D.
    Acta Med Croatica; 2004 Apr; 58(2):129-34. PubMed ID: 15208798
    [Abstract] [Full Text] [Related]

  • 7. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 8. [Prevention with angiotensin-converting enzyme (ACE) inhibitors].
    Ertl G, Gaudron P, Neubauer S, Bauer B.
    Z Kardiol; 1992 Jun; 81 Suppl 4():205-10. PubMed ID: 1290300
    [Abstract] [Full Text] [Related]

  • 9. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR, Noll G, Lüscher TP.
    Schweiz Med Wochenschr; 1997 Apr 12; 127(15):636-49. PubMed ID: 9198890
    [Abstract] [Full Text] [Related]

  • 10. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G, Nicolosi GL, Chiariello M, Ferrari R, Remme P, Tavazzi L.
    Ital Heart J; 2005 Nov 12; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [Abstract] [Full Text] [Related]

  • 11. [The value of ACE inhibitors in heart failure (mechanism of action)].
    Drexler H.
    Z Kardiol; 1992 Nov 12; 81 Suppl 4():85-91. PubMed ID: 1290308
    [Abstract] [Full Text] [Related]

  • 12. [New aspects of ACE inhibitor treatment of heart failure].
    Dietz R, Osterziel KJ.
    Z Kardiol; 1996 Nov 12; 85 Suppl 6():241-6. PubMed ID: 9064971
    [Abstract] [Full Text] [Related]

  • 13. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 14. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 21; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 15. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA, Molnar J, Arora RR.
    Diabetes Obes Metab; 2008 Jan 21; 10(1):41-52. PubMed ID: 18095949
    [Abstract] [Full Text] [Related]

  • 16. Effect of ACE inhibition on neurohormones.
    Remme WJ.
    Eur Heart J; 1998 Sep 21; 19 Suppl J():J16-23. PubMed ID: 9796836
    [Abstract] [Full Text] [Related]

  • 17. Effect of ACE inhibition on myocardial ischaemia.
    Ferrari R.
    Eur Heart J; 1998 Sep 21; 19 Suppl J():J30-5. PubMed ID: 9796838
    [Abstract] [Full Text] [Related]

  • 18. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Julius S.
    Am Heart J; 2004 Nov 21; 148(5):747-54. PubMed ID: 15523303
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.
    Asselbergs FW, van Gilst WH.
    Curr Opin Cardiol; 2007 Jul 21; 22(4):267-72. PubMed ID: 17556876
    [Abstract] [Full Text] [Related]

  • 20. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R, Papa K, Bernocchi P, Gimbatti OJ, Golcea SS, Bettini A, Ceconi C.
    Ital Heart J; 2005 Nov 21; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.